Multivariate analysis of adverse prognostic factors in allogeneic HSCT for pediatric Hodgkin lymphoma associated with increased NRM, relapse rate, PFS, and OS
| . | RR . | CI . | P . |
|---|---|---|---|
| Nonrelapse mortality | |||
| Female vs male sex | 2.9 | 1.1-7.7 | .02 |
| Mismatched vs matched donor | 3.1 | 1.0-9.9 | .05 |
| Relapse rate | |||
| Poor vs good performance status | 3.2 | 1.2-8.4 | .02 |
| Refractory vs sensitive disease | 2.1 | 1.0-4.4 | .04 |
| Reduced vs myeloablative conditioning* | |||
| First 9 mos after HSCT | No differences | ||
| More than 9 mos after HSCT | 4.4 | 1.0-19.0 | .05 |
| Progression-free survival | |||
| Refractory vs sensitive disease | 2.8 | 1.6-4.9 | < .001 |
| CMV positivity in donor and/or recipient | 2.9 | 1.3-6.5 | .01 |
| Mismatched vs matched donor | 2.6 | 1.1-5.8 | .02 |
| Reduced vs myeloablative conditioning* | |||
| First 9 months after HSCT | No differences | ||
| More than 9 months after HSCT | 3.8 | 1.1-11.5 | .02 |
| Year of HSCT, before 2002 vs 2002-2005 | 2.0 | 1.0-4.2 | .05 |
| Overall survival | |||
| Refractory vs sensitive disease | 2.9 | 1.6-5.6 | .001 |
| CMV positivity in donor and/or recipient | 4.6 | 1.7-12.5 | .003 |
| Mismatched vs matched donor | 2.9 | 1.1-7.4 | .03 |
| . | RR . | CI . | P . |
|---|---|---|---|
| Nonrelapse mortality | |||
| Female vs male sex | 2.9 | 1.1-7.7 | .02 |
| Mismatched vs matched donor | 3.1 | 1.0-9.9 | .05 |
| Relapse rate | |||
| Poor vs good performance status | 3.2 | 1.2-8.4 | .02 |
| Refractory vs sensitive disease | 2.1 | 1.0-4.4 | .04 |
| Reduced vs myeloablative conditioning* | |||
| First 9 mos after HSCT | No differences | ||
| More than 9 mos after HSCT | 4.4 | 1.0-19.0 | .05 |
| Progression-free survival | |||
| Refractory vs sensitive disease | 2.8 | 1.6-4.9 | < .001 |
| CMV positivity in donor and/or recipient | 2.9 | 1.3-6.5 | .01 |
| Mismatched vs matched donor | 2.6 | 1.1-5.8 | .02 |
| Reduced vs myeloablative conditioning* | |||
| First 9 months after HSCT | No differences | ||
| More than 9 months after HSCT | 3.8 | 1.1-11.5 | .02 |
| Year of HSCT, before 2002 vs 2002-2005 | 2.0 | 1.0-4.2 | .05 |
| Overall survival | |||
| Refractory vs sensitive disease | 2.9 | 1.6-5.6 | .001 |
| CMV positivity in donor and/or recipient | 4.6 | 1.7-12.5 | .003 |
| Mismatched vs matched donor | 2.9 | 1.1-7.4 | .03 |
Those factors differing with P ≤ .05 are shown.
CI indicates confidence interval; CMV, cytomegalovirus; HSCT, hematopoietic stem cell transplantation; and RR, relative risk.
The covariate “type of conditioning” significantly influenced relapse rate and PFS starting at 9 months after allogeneic HSCT.